### **Overview** **Sudarshan Pharma Industries Limited (SPIL)**, founded in 2008 and headquartered in Mumbai, is a fully integrated manufacturer in the pharmaceutical and specialty chemicals sectors. Operating across the entire pharmaceutical value chain—from R&D and chemical raw materials to intermediates, APIs, and finished formulations—SPIL has established itself as a dynamic player in both domestic and international markets. The company went public via an IPO on the BSE SME platform in March 2023 and has since executed an aggressive growth strategy through acquisitions, vertical integration, and expansion into high-growth therapeutic areas. SPIL is led by **Hemal V. Mehta (Chairman & Managing Director)** and **Sachin V. Mehta (Joint Managing Director & CFO)**, both with over 25 years of cumulative experience in pharmaceutical and chemical manufacturing, innovation, and supply chain excellence. --- ### **Recent Strategic Developments (2025)** #### **• $255 Million Growth Investment & Facility Acquisition (Sep 2025)** - SPIL has committed **$255 million (approx. Rs 2,150 crores)** to strengthen vertical integration, operational efficiency, and product diversification. - A key move under this program was the **acquisition of a fully operational API manufacturing facility from Srigen Lifesciences Private Limited** in Telangana (PIN 501401) for **Rs 25.5 crores**. - The facility comes with **80 kilolitres of reactor capacity** and is **GMP-compliant**, with existing regulatory approvals. - It is strategically focused on producing **high-value, complex molecules** including: - Ropivacaine - Bupivacaine - Probenecid - Sitagliptin - Apixaban - Rivaroxaban - This acquisition enables **faster product launch timelines**, immediate scale-up, and access to **regulated and semi-regulated markets**, with shortened approval cycles and reduced regulatory costs. #### **• Strategic Acquisition of Srigen’s Facility – Operational & Strategic Benefits** - The acquired facility strengthens SPIL’s **manufacturing footprint** and enhances its ability to serve global markets with **quality, agility, and compliance**. - SPIL will leverage **50 patented or patent-protected Key Starting Materials (KSMs)** developed by Srigen, now under SPIL’s control. - These include commercial-scale intermediates like **Molnupiravir Sodium Intermediate, Vildagliptin KSM, and Sitagliptin KSM**. - The transaction supports SPIL’s long-term vision of building a **scalable, compliance-driven manufacturing infrastructure** for domestic and export expansion. --- ### **Core Business Segments & Product Portfolio** #### **• Pharmaceutical Products** SPIL manufactures and markets: - **Active Pharmaceutical Ingredients (APIs)** - **Intermediates** - **Finished Dosage Forms (FDFs)** - **Oncology APIs**: Gemcitabine, Apalutamide, Olaparib, Cisplatin, Lenalidomide, T9 (experimental) - **Cardiac & Chronic Care**: Aplutamide, Crizotinib - **Vitamins**: Thiamine Hydrochloride (B1), Pyridoxine Hydrochloride (B6) – **claimed first Indian manufacturer** - **Other APIs**: Fluconazole, Pregabalin, Mefenamic Acid, Methylcobalamin, Levocetrizine Dihydrochloride, Chlorozoxazone #### **• Specialty Chemicals** - Solvents: Acetonitrile, 1,4-Dioxane, THF, 2-Methyl THF, DMF/DMSO, Diethyl Ether - Key Chemicals: Pyridine, Iodine, Meta Xylene, 4-MBA, 4-Methyl Acetophenone - **In Development**: N-Heptane, Heptylidene Acetone, 10-Undecyn-1-ol, Oxcarbazepine #### **• Branded Formulations & Innovations** SPIL has launched several India-first products: - **Jivan Kit & Jivan Prash**: Immunity-boosting Ayurvedic formulations - **Set Down**: Combines allopathic and Ayurvedic ingredients for digestive health - **HART KIT LD**: Emergency cardiac loading dose for heart attacks (patent pending) - **Mouth-Dissolving Strips**: For cold, cough, thyroid, and allergies under the **Love Bird™** brand - **Curcumin Logingis**: For cancer and psoriasis - **Pulmo Relief**, **Fix Pollen**, **Flupimac**, **METFOCAL**, **ENAMOL SP** --- ### **Manufacturing & Operational Infrastructure (2025)** - **Existing Facilities**: - **Maharashtra (Palghar)**: Unit 2 for oral liquids (6,000 L/day), capsules, packaging. FDA-registered for 50+ products including antibiotics, antipyretics, antifungals. - **Gujarat & Maharashtra (Jejuri, via Ratna Lifesciences)**: Oncology API manufacturing with **2 metric tonnes annual capacity (expandable to 15 MT)**. - **New Developments**: - **Palghar Multi-Purpose Plant**: Set to be operational by **March 2026**, supporting PLI objectives. - **Dehradun R&D & Formulation Center**: DSIR-approved, land acquired, construction underway. Will develop oral, liquid, and injectable dosage forms. - **New Oral Solid Dosage Facility**: Planned with **FDA, WHO, GMP, GLP certification** for international compliance. - **R&D Capabilities**: - In-house R&D with focus on **new molecule development, process innovation, and import substitution**. - Collaboration with **Dr. Shrikant Ghodse (Mumbai)** and **Dr. William Selvamurthy (Amity University)** for **nanotechnology and pharmaceutical innovation**. - **Patents Filed**: Manufacturing processes for Vitamin B1, B6, and related intermediates; Cardiac First Aid Kit. - **Government Support**: - Approved under **Production-Linked Incentive (PLI) Scheme** for KSMs, DIs, and APIs. - Focus on domestic manufacturing of critical APIs to reduce import dependence. - **Patented bioplastic technology** from stubble, aloe vera waste, PVA, and glycerol – secured via tech transfer from **Uttaranchal University**. --- ### **Subsidiaries & Investments** | Subsidiary | Stake | Key Focus | |-----------|-------|---------| | **Life Science Chemical Pvt. Ltd.** | 100% | API intermediates (Gemcitabine HCl, Imatinib Mesylate) | | **Ratna Lifesciences Pvt. Ltd.** | 100% | Oncology APIs and intermediates | | **Ishwari Healthcare Pvt. Ltd.** | 51% (acquired Apr 2025 for Rs 21.5 cr) | Medical devices: sutures, catheters, meshes | | **Sudarshan Maven Pharma Pvt. Ltd.** | 70% (incorporated Aug 2024) | APIs, nutraceuticals, biologics | | **Sudarshan Pharma Lifesciences Pvt. Ltd.** | 100% | Pharma and healthcare trading | | **Sudarshan Pharma Industries Pvt. Ltd. (Singapore)** | 100% | International business operations | | **Cibachem General Trading LLC (Dubai)** | 100% | Export and distribution in GCC and MENA | --- ### **Global Expansion & Export Strategy** - **Export Markets**: Over **10 countries**, including UK, Australia, UAE, Oman, Taiwan, Sri Lanka, Bangladesh, Jordan, Saudi Arabia, Nepal, and multiple African nations (Nigeria, Kenya, Uganda, Congo, Rwanda, Mali, Ghana, Somalia). - **Export Revenue Targets**: - **FY2025–26**: ₹100 crore (non-regulated markets: Africa, MENA, Gulf) – primarily self-manufactured APIs and formulations. - **FY2026–27**: ₹200 crore (regulated/semi-regulated markets) via high-value API portfolio. - **FY2027–28**: ₹300 crore with **foreign depots**, increased registrations, and OTC brand presence. - **Strategic Partnerships**: - **MoU with Ardes Laboratories (Nov 2024)**: CDMO collaboration to scale production across shared sites. - Supply partnerships with major pharma firms: **Sai Life Sciences, Neuland Labs, Aurobindo Pharma, DMS Laboratories**. - Approved vendor for **multinational pharma and chemical companies**. - **Distribution Rights in India**: - **5-year agreements** for: - Sucralose (market: USD 3.11B → USD 3.61B by 2028) - HPMC & L-HPC (market: USD 1.94B → USD 2.85B by 2030) - Beta Cyclodextrin, Mannitol, Acesulfame K - Imports of L-APC and specialty chemical grades. --- ### **Growth Strategy & Vision** SPIL follows a **vertically integrated business model**, with current emphasis on **APIs and intermediates**, followed by a **gradual shift toward branded finished formulations and OTC products**. #### **Short to Medium Term (Next 2–3 Years)** - Expand manufacturing capacity via new Palghar and Dehradun facilities. - Scale oncology API production. - Launch new dosage forms (strips, injectables). - Strengthen export presence in **regulated and semi-regulated markets**. #### **Long-Term Vision** - Build **global brand recognition** in pharmaceuticals and specialty chemicals. - Address critical **global health challenges**: cancer, heart disease, diabetes, AIDS. - Become a **preferred CDMO partner** with strong R&D and compliance. - **Lead domestic API manufacturing** under **Aatmanirbhar Bharat** objectives. --- ### **Key Competitive Advantages** 1. **End-to-End Integration**: Full control over R&D, sourcing, manufacturing, and distribution. 2. **Regulatory Compliance**: FDA, WHO, GMP-approved facilities. 3. **Innovation-Centric Culture**: 15+ patents filed, first in India for B1/B6 API synthesis. 4. **Strategic Acquisitions**: Ratna Lifesciences (oncology), Srigen (API capability), Ishwari Healthcare (medical devices). 5. **Dual Market Focus**: Strong B2B API supply to pharma giants + B2C health brand presence. 6. **Export Scalability**: Ready infrastructure from acquired facilities for fast global entry. ---